Émilie Bortolussi-Courval, Connor Prosty, Jimin J. Lee, Lisa M. McCarthy, Emily G. McDonald, Todd C. Lee
{"title":"每周与每天服用胆钙化醇补充血清维生素 D (25(OH)D) 缺乏症的疗效:随机对照试验的系统回顾和荟萃分析。","authors":"Émilie Bortolussi-Courval, Connor Prosty, Jimin J. Lee, Lisa M. McCarthy, Emily G. McDonald, Todd C. Lee","doi":"10.1111/bcpt.14092","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background/rationale</h3>\n \n <p>Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly <i>versus</i> daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.</p>\n </section>\n \n <section>\n \n <h3> Findings</h3>\n \n <p>Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3–6.9, <i>p</i> = 0.6, favouring weekly dosing, <i>I</i><sup>2</sup> = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3–2.1, <i>p</i> = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.</p>\n </section>\n </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 6","pages":"685-692"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617645/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials\",\"authors\":\"Émilie Bortolussi-Courval, Connor Prosty, Jimin J. Lee, Lisa M. McCarthy, Emily G. McDonald, Todd C. Lee\",\"doi\":\"10.1111/bcpt.14092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background/rationale</h3>\\n \\n <p>Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly <i>versus</i> daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Findings</h3>\\n \\n <p>Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3–6.9, <i>p</i> = 0.6, favouring weekly dosing, <i>I</i><sup>2</sup> = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3–2.1, <i>p</i> = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.</p>\\n </section>\\n </div>\",\"PeriodicalId\":8733,\"journal\":{\"name\":\"Basic & Clinical Pharmacology & Toxicology\",\"volume\":\"135 6\",\"pages\":\"685-692\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617645/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic & Clinical Pharmacology & Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.14092\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.14092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景/原理:每周补充胆钙化醇可替代每日补充,以减轻用药方案复杂和维生素D缺乏症患者的药片负担,但支持这种转换的证据尚不明确:我们旨在确定每周补充胆钙化醇是否优于每天补充胆钙化醇,以补充维生素 D 缺乏症患者的营养:我们对涉及基线维生素 D 缺乏症患者的随机对照试验进行了系统回顾(结果:共纳入 8 项试验,涉及 542 名患者):八项涉及 542 名患者的试验被纳入分析。每周服用胆钙化醇和每天服用胆钙化醇在纠正维生素 D 过低方面没有显著差异(OR = 1.5,95% CI = 0.3-6.9,P = 0.6,倾向于每周服用,I2 = 85.3%)。一项排除其他健康患者的敏感性分析也得出了类似的结果(OR = 0.8,95% CI = 0.3-2.1,p = 0.6)。大多数研究存在偏倚风险;不同剂量的比较增加了异质性:有限的直接证据支持将胆钙化醇剂量从每天一次改为每周一次;但是,每周一次的补充并不会明显降低补充水平,而且还能减轻患者的日常用药负担。
Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials
Background/rationale
Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.
Objective
We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.
Methods
We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.
Findings
Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3–6.9, p = 0.6, favouring weekly dosing, I2 = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3–2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.
Conclusions
Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.